Climb Bio, Inc. (NASDAQ: CLYM) is a Healthcare company (Biotechnology) with a market capitalization of $574M. The Maz Rating grades it against the other companies in its sector.
Climb Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.78, Climb Bio, Inc. trades at 3.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -30.6%, return on invested capital of -29.1% and a free cash flow yield of -9.4%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 26.58. Over the past 52 weeks the share price ranged from $1.64 to $18.33, with a beta of 0.07.
Climb Bio, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Climb Bio, Inc. (CLYM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.8% / 30% · Interest income / Revenue 232500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 232500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 232500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.06% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 74.6% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 232500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 86.8% / 33.33% · (Cash+Recv) / Total Assets 86.8% / 33.33% · Interest income / Revenue 232500000.0% / 5% | Fail |
No. As of September 2026, Climb Bio, Inc. (CLYM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Climb Bio, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 232500000.0% of each dividend: Climb Bio, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.